Journal article
[ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
MS Hofman, J Violet, RJ Hicks, J Ferdinandus, S Ping Thang, T Akhurst, A Iravani, G Kong, A Ravi Kumar, DG Murphy, P Eu, P Jackson, M Scalzo, SG Williams, S Sandhu
Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2018
Abstract
Background: Progressive metastatic castration-resistant prostate cancer is a highly lethal disorder and new effective therapeutic agents that improve patient outcomes are urgently needed. Lutetium-177 [ 177 Lu]-PSMA-617, a radiolabelled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA) enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer. We aimed to investigate the safety, efficacy, and effect on quality of life of [ 177 Lu]-PSMA-617 in men with metastatic castration-resistant prostate cancer who progressed after standard treatments. Methods: In this single-arm, single-centre, phase 2 trial, we recruited men (aged 18 ..
View full abstractGrants
Awarded by Australian Nuclear Science and Technology Organisation
Funding Acknowledgements
This study was sponsored by the Peter MacCallum Cancer Centre (Melbourne, VIC, Australia). <SUP>177</SUP>Lu (no carrier added) was supplied by the Australian Nuclear Science and Technology Organisation (ANSTO, Sydney, Australia) and PSMA-617 by Advanced Biochemical Compounds (ABX, Radeberg, Germany). MSH is supported by a Clinical Fellowship Award from the Peter MacCallum Foundation and a Movember Clinical Trials Award awarded through the Prostate Cancer Foundation of Australia's Research Program. SS is supported by a Clinical Fellowship Award from the Peter MacCallum Foundation and by the John Mills Young Investigator Award from Prostate Cancer Foundation of Australia. RJH is supported by a National Health and Medical Research Foundation of Australia Practitioner Fellowship. We thank the nuclear medicine and nursing staff at the Peter MacCallum Cancer Centre and all the patients who agreed to participate in the study. We also thank Mathias Bressel (biostatistican) for analysis of the quality-of-life data.